14/09/2018 22:00:00

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee of Alder’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 40,000 shares of Alder’s common stock to a new employee under Alder’s 2018 Inducement Award Plan, effective September 12, 2018.

The stock option will vest with respect to 25% of the shares underlying the option one year after the employee’s employment start date and the remaining 75% of the shares underlying the option will vest in equal monthly installments over the 36 month period following the one year anniversary of the employee’s employment start date, subject to the employee’s continued service to Alder through each relevant vesting date.  The option has a ten year term and an exercise price of $18.20 per share, which is equal to the closing price of Alder’s common stock on September 12, 2018.

The stock option was granted as an inducement material to the employee’s entering into employment with Alder in accordance with Nasdaq Listing Rule 5635(c)(4).

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP). Eptinezumab is currently in late-stage clinical development and, if approved, will be the first-to-market infusion therapy for migraine prevention. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, visit www.alderbio.com.

Investor Relations Contact:                                        

Michael Schaffzin

Stern Investor Relations, Inc.

212-362-1200

michael@sternir.com

Media Contact: 

Ashley Cadle

TogoRun

a.cadle@togorun.com

310.463.0143

Alder 1C Logo with R (002) (1).JPG

Related content
11 Jul - 
Alder BioPharmaceuticals® Presents New Data on Migraine..
08 Jul - 
Alder BioPharmaceuticals® to Showcase 14 New Data Prese..
19 Jun - 
Alder BioPharmaceuticals® to Webcast Upcoming Breakfast..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SolarWinds New APAC Research Shows Insider Threats Rank as Top Cybersecurity Threat Concern
2
ROSEN, A TOP RANKED LAW FIRM, Reminds RCI Hospitality Holdings, Inc. Investors of July 22nd Deadline in Securities Class Action – RICK
3
Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
4
ROSEN, A TOP RANKED LAW FIRM, Reminds Community Health Systems, Inc. Investors of Important July 29th Deadline in the Securities Class Action– CYH
5
Black Creek Group Industrial Real Estate Investment Platform to be acquired by Prologis for $3.99 Billion

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 July 2019 10:01:37
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB7 - 2019-07-16 11:01:37 - 2019-07-16 10:01:37 - 1000 - Website: OKAY